The Business of AI in Life Sciences

Axial partners with great founders and inventors. We invest in early-stage life sciences companies often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company . We are excited to be in business with you - email us at   info@axialvc.com

Artificial intelligence (AI) has the potential to transform many parts of life sciences from preclinical drug development and healthcare to synthetic biology and diagnostics. Basic research in AI has made major strides over the last 5 years, and when combined with biologists working with data as much as they work on the bench, the technology is changing how biology is studied and engineered.

As a result, AI-first companies in life sciences at first may not look like traditional companies. Whereas, traditional life sciences companies usually have a core set of IP or are based on a biological hypothesis, AI life sciences companies often look like R&D shops or services companies at first. This transition from services to a product focus has several trade offs but provides the potential to build a more scalable business model. In particular, these companies face challenges with:

Leave a Comment